Diamant M, Nauck MA, Shaginian R, Malone JK, Cleall S, Reaney M, et al
In parallel, triple agonists simultaneously targeting GIP, GLP-1, and GCG receptors are also under investigation, aiming to deliver greater WL and metabolic improvements than mono- or dual-agonists
Care connected to this topic Altmed Medical Center offers urgent care, primary care, occupational health, telehealth, and medical weight-loss services in Manassas
Where the peptides differ significantly is in their side effect profiles and titration timelines
The weight loss drugs in question include not only GLP-1 products like Ozempic and Wegovy but also drugs in the Food and Drug Administrations pipeline such as Mounjaro and Rybelsus